¿Estamos diagnosticando la diabetes demasiado tarde? | 28 MAY 17

¿Qué es la diabetes subclínica?

Las personas normoglucémicas también tienen riesgo de sufrir las complicaciones y comorbilidades de la diabetes
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

Referencias bilibiográficas

  1. ABDUL-GHANI MA AND RA DEFRONZO. 2009. Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes Care 32(Suppl 2): S194-198.
  2. AHRÉN B. 2009. Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes 58: 726-731.
  3. ALBERTI KGMM ET AL. 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640-1645.
  4. AMES BN. 2006. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc Natl Acad Sci U S A 103: 17589-17594.
  5. ASSOCIATION AD. 1998. Consensus Development Conference on Insulin Resistance: 5-6 November 1997. Diabetes Care 21: 310-314.
  6. ASSOCIATION AD. 2014. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 37: S81-S90.
  7. ASSOCIATION AD. 2016. 2. Classification and Diagnosis of Diabetes. Diabetes Care 39: S13-S22.
  8. ATKINSON FS, FOSTER-POWELL K AND BRANDMILLER JC. 2008. International Tables of Glycemic Index and Glycemic Load Values: 2008. Diabetes Care 31: 2281-2283.
  9. BABIO N ET AL. 2014. Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial. CMAJ 186: E649-657.
  10. BAO J, ATKINSON F, PETOCZ P, WILLETT WC AND BRAND-MILLER JC. 2011. Prediction of postprandial glycemia and insulinemia in lean, young, healthy adults: glycemic load compared with carbohydrate content alone. Am J Clin Nutr 93: 984-996.
  11. BAO J, DE JONG V, ATKINSON F, PETOCZ P AND BRANDMILLER JC. 2009. Food insulin index: physiologic basis for predicting insulin demand evoked by composite meals. Am J Clin Nutr 90: 986-992.
  12. BARR ELM, BOYKO EJ, ZIMMET PZ, WOLFE R, TONKIN AM AND SHAW JE. 2009. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 52: 415-424.
  13. BARR ELM ET Al. 2010. HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) study. Diabetologia 53: 79-88.
  14. BASH LD, SELVIN E, STEFFES M, CORESH J AND ASTOR BC. 2008. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis risk in communities (aric) study. Arch Intern Med 168:2440-2447.
  15. BOIZEL R, BENHAMOU PY, LARDY B, LAPORTE F, FOULON T AND HALIMI S. 2000. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 23: 1679-1685.
  16. BONORA E ET AL. 2007. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 30:318-324.
  17. BOWER RL AND DL HAY. 2016. Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development. Br J Pharmacol 173:1883-1898.
  18. BOZZETTO L ET AL. 2016. Extra-Virgin Olive Oil Reduces Glycemic Response to a High-Glycemic Index Meal in Patients With Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Care 39: 518-524.
  19. BRUDEVOLD R, HOLE T AND HAMMERSTRØM J. 2008. Hyperferritinemia Is Associated with Insulin Resistance and Fatty Liver in Patients without Iron Overload. PLOS ONE 3: e3547.
  20. BUDOFF MJ ET AL. 2013. Progression of Coronary Calcium and Incident Coronary Heart Disease Events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 61: 1231-1239.
  21. BUTLER AE, JANSON J, BONNER-WEIR S, RITZEL R, RIZZA RA AND BUTLER PC. 2003. beta-Cell Deficit and Increased beta-Cell Apoptosis in Humans With Type 2
  22. Diabetes. Diabetes 52: 102-110.
  23. CABRERA DE LEÓN A ET AL. 2015. C-peptide as a risk factor of coronary artery disease in the general population. Diab Vasc Dis Res 12: 199-207.
  24. CAHILL GF. 2006. Fuel metabolism in starvation. Annu Rev Nutr 26: 1-22.
  25. CANELLA DS ET AL. 2014. Ultra-Processed Food Products and Obesity in Brazilian Households (2008-2009). PLOS ONE 9: e92752.
  26. CEFALU WT. 2016. “Prediabetes”: Are There Problems With This Label? No, We Need Heightened Awareness of This Condition! Diabetes Care 39: 1472-1477.
  27. CHIA CW, ODETUNDE JO, KIM W, CARLSONOD, FERRUCCI L AND EGAN JM. 2014. GIP Contributes to Islet Trihormonal Abnormalities in Type 2 Diabetes. J Clin
  28. Endocrinol Metab 99: 2477-2485.
  29. COLAGIURI S ET AL. 2011. Glycemic Thresholds for Diabetes-Specific Retinopathy Implications for diagnostic criteria for diabetes. Diabetes Care 34: 145-150.
  30. COOPER GJ, WILLIS AC, CLARK A, TURNER RC, SIM RB AND REID KB. 1987. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84: 8628-8632.
  31. CORDAIN L, EADES MR AND EADES MD. 2003. Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comp Biochem Physiol A Mol Integr Physiol 136: 95-112.
  32. CRANE PK ET AL. 2013. Glucose Levels and Risk of Dementia. N Engl J Med 369: 540-548.
  33. CUNNANE SC AND CRAWFORD MA. 2003. Survival of the fattest: fat babies were the key to evolution of the large human brain. Comp Biochem Physiol A Mol Integr Physiol 136: 17-26.
  34. DABELEA D ET AL. 2014. PRevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 311: 1778-1786.
  35. DCCT. 1993. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med 329: 977-986.
  36. DCCT-EDIC. 2000. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342: 381-389.
  37. DECODE STUDY GROUP. 1999. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. The Lancet 354: 617-621.
  38. DECODE STUDY GROUP, EUROPEAN DIABETES EPIDEMIOLOGY GROUP. 2003. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26: 688-696.
  39. DEFRONZO RA. 1988. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687.
  40. DEFRONZO RA, TOBIN JD AND ANDRES R. 1979. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-223.
  41. DESPRÉS JP ET AL. 1996. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 :952-957.
  42. DEVECI E ET AL. 2009. Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clin Cardiol 32: 32-36.
  43. DEWITT DE AND IB HIRSCH. 2003. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 289:2254-2264.
  44. DOBBS R ET AL. 1975. Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187: 544-547.
  45. DPP - DIABETES PREVENTION PROGRAM. 2002. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. Diabetes Prevention Program Research Group. N Engl J Med 346: 393-403.
  46. EBBELING CB, LEIDIG MM, FELDMAN HA, LOVESKY MM AND LUDWIG DS. 2007. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA 297: 2092-2102.
  47. ESTRUCH R ET AL. 2016. Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. Lancet Diabetes Endocrinol 4: 666-676.
  48. ESTRUCH R ET AL. 2013. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. research-article. (22 August 2016).
  49. FEDERATION. 2015. IDF Diabetes Atlas. P. In: International Diabetes Federation. FEINMAN RD ET AL. 2015. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutr Burbank Los Angel Cty Calif 31: 1-13.
  50. FLOYD JC, FAJANS SS, PEK S AND CHANCE RE. 1976. A newly recognized pancreatic polypeptide; plasma levels in health and disease. Recent Prog Horm Res 33: 519-570.
  51. FORGA LLENAS L, GOÑI IRIARTE MJ, CAMBRA CONTIN K, IBÁÑEZ BEROIZ B, CHUECA GUENDULAIN M AND BERRADE ZUBIRI S. 2015. Incidence and temporal trends of childhood type 1 diabetes between 1975 and 2012 in Navarre (Spain). Gac Sanit SESPAS 29: 51-54.
  52. FOROUHI NG AND WAREHAM NJ. 2014. Epidemiology of diabetes. Medicine (Baltimore) 42: 698-702.
  53. GANNON MC AND NUTTALL FQ. 2004. Effect of a highprotein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. Diabetes 53: 2375-2382.
  54. GARBER AJ ET AL. 2016. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract 22: 84-113.
  55. GARDNER CD ET AL. 2007. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 297: 969-977.
  56. GARG MK, DUTTA MK and MAHALLE N. 2011. Study of beta-cell function (by HOMA model) in metabolic syndrome. Indian J Endocrinol Metab 15: S44-49.
  57. GASTALDELLI A, FERRANNINI E, MIYAZAKI Y, MATSUDA M, DEFRONZO RA and SAN ANTONIO METABOLISM STUDY. 2004. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47: 31-39.
  58. GODOY-MATOS AF. 2014. The role of glucagon on type 2 diabetes at a glance. Diabetol Metab Syndr 6: 91.
  59. GOTO A ET AL. 2016. High hemoglobin A1c levels within the non-diabetic range are associated with the risk of all cancers. Int J Cancer 138: 1741-1753.
  60. GRUNDY SM ET AL. 2005. Diagnosis and Management of the Metabolic Syndrome. Circulation 112: 2735-2752.
  61. GUERREIRO LH, DA SILVA D, SOLA-PENNA M, MIZURINI DM and LIMA LMTR. 2013. Amylin induces hypoglycemia in mice. An Acad Bras Cienc 85: 349-354.
  62. HALL KD ET AL. 2015. Calorie for Calorie, Dietary Fat Restriction Results in More Body Fat Loss than Carbohydrate Restriction in People with Obesity. Cell Metab 22: 427-436.
  63. HANLEY AJG, WILLIAMS K, STERN MP AND HAFFNER SM. 2002. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25:1177-1184.
  64. HARJUTSALO V, SJÖBERG L AND TUOMILEHTO J. 2008. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. The Lancet 371: 1777-1782.
  65. HÄTÖNEN KA ET AL. 2006. Methodologic considerations in the measurement of glycemic index: glycemic response to rye bread, oatmeal porridge, and mashed potato. Am J Clin Nutr 84: 1055-1061.
  66. HAY DL, CHEN S, LUTZ TA, PARKES DG AND ROTH JD. 2015. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev 67: 564-600. HECHT HS. 2015. Coronary artery calcium scanning: past, present, and future. JACC Cardiovasc. Imaging 8: 579-596.
  67. HOLDEN SE ET AL. 2013. The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010. Diabetes Obes Metab 15: 844-852.
  68. HUO X ET AL. 2016. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol 4: 115-124.
  69. IKEDA F ET AL. 2013. Haemoglobin A1c even within nondiabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol 12: 164.
  70. INSTITUTE OF MEDICINE. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). P. in.: National Academies Press, Washington, D.C.
  71. INSTITUTE OF MEDICINE. 2006. Dietary Reference Intakes Research Synthesis: Workshop Summary. P. In: National Academies Press, Washington, D.C.
  72. JENKINS DJ ET AL. 1981. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 34: 362-366.
  73. JOHNSON JL, DUICK DS, CHUI MA and ALDASOUQI SA. 2010. Identifying prediabetes using fasting insulin levels. Endocr Pract 16: 47-52.
  74. JONES AG AND HATTERSLEY AT. 2013. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30: 803-817.
  75. KAHLEOVA H ET AL. 2014. Eating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: a randomised crossover study. Diabetologia 57:1552-1560.
  76. KAHN SE ET AL. 1998. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47: 640-645.
  77. KARROWNI W ET AL. 2013. Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 33: 2245-2251.
  78. KATO M, NODA M, SUGA H, MATSUMOTO M AND KANAZAWA Y. 2009. Fasting plasma glucose and incidence of diabetes --- implication for the threshold for impaired fasting glucose: results from the populationbased Omiya MA cohort study. J Atheroscler Thromb 16:857-861.
  79. KAUR B AND HENRY J. 2014. Micronutrient status in type 2 diabetes: a review. Adv Food Nutr Res 71: 55-100.
  80. KHAW KT, WAREHAM N, BINGHAM S, LUBEN R, WELCH A AND DAY N. 2004. Association of hemoglobin A1c with cardiovascular disease and mortality in adults:the European prospective investigation into cancer in Norfolk. Ann Intern Med 141: 413-420.
  81. KOHNER EM ET AL. 1998. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 116(3): 297-303.
  82. KOPP W. 2003. High-insulinogenic nutrition--an etiologic factor for obesity and the metabolic syndrome? Metabolism 52: 840-844.
  83. KRAFT JR. 1975. Detection of Diabetes Mellitus In Situ (Occult Diabetes). Lab Med 6: 10-22.
  84. KRAFT JR. 2008. Diabetes Epidemic & You. P. In.: Trafford Publishing.
  85. KRIS-ETHERTON P, ECKEL RH, HOWARD BV, JEOR SS AND BAZZARRE TL. 2001. Lyon Diet Heart Study. Circulation 103: 1823-1825.
 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023